Patients with allergic rhinitis or chronic idiopathic urticaria. Patients with seasonal allergic rhinitis (SAR) have indicated trends towards greater efficacy with the 20-mg than the 10-mg dose. Also indicated in the inhibition of histamine-induced wheal and flare reactions of the skin due to allergens or medications that may produce allergic reactions in certain hypersensitive patients. Ebastine does not appear to be associated with any significant cardiac adverse events. Once-daily ebastine offers an effective and well-tolerated alternative to other 2nd-generation antihistamines in current use for the 1st-line treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.